Effects of a 12-week multi-strain probiotics supplementation on circulating endotoxin and antioxidant enzymes among overweight/obese Saudi adults: Randomized, double-blind, placebo-controlled trial

Authors: AlMalki, Samira M; Alfawaz, Hanan A; Sabico, Shaun; Alnaami, Abdullah M; Alshiban, Noura M; Hussain, Syed D; Ibrahim, Razi A; Al-Daghri, Nasser M

Source journal: Medicine (2026-11-20)

DOI: 10.1097/MD.0000000000051573

Abstract

BACKGROUND: Several clinical trials have indicated the favorable effects of probiotics in lowering the risk of chronic diseases such as obesity; however, few of them have explored the potential in altering obesity-related biomarkers, and the present study aimed to fill this gap. METHODS: A total of 93 overweight/obese adults (males and females, aged 19-40 years) were recruited at the clinical facility of King Saud University Medical City, Riyadh, Saudi Arabia, between March 2022 and January 2023 in a double-blind, placebo-controlled, randomized clinical trial. In this study, the subjects were randomly assigned to receive 30 x 109 colony-forming units HEXBIO(R) containing 3 Bifidobacterium and 3 Lactobacillus species (N = 44; 64% subjects) or a placebo containing the same excipients without the live bacterial strains (N = 49; 76% subjects); all subjects consumed the product twice daily for 3 months. RESULTS: At baseline, anthropometric measurements, the liver profile, and antioxidant enzymes did not differ significantly between the probiotic and placebo groups. Following the 12-week intervention, within-group analysis revealed significant increases in the levels of superoxide dismutase (0.06 +/- 0.1 vs 0.19 +/- 0.29 U/mL; P = .02) and glutathione peroxidase (GPX1; 0.66 +/- 0.23 vs 0.76 +/- 0.2; P = .01) among all probiotic-supplemented subjects. After stratification by sex, significant favorable changes in superoxide dismutase (0.03 +/- 0.04 vs 0.29 +/- 0.4; P = .05) and GPX1 (0.66 +/- 0.26 vs 0.82 +/- 0.18; P = .03) were observed only in the male probiotics group, and between-group comparisons showed a modest but clinically significant difference only in GPX1 in favor of the probiotics group (P = .04). These changes were not observed in females. No differences were observed in the levels of endotoxins and liver enzymes over time in both groups. CONCLUSION: The administration of multi-strain probiotic supplements for 3 months, along with dietary intervention, was associated with a modest favorable change in GPX1 levels in males, with no apparent changes in circulating endotoxins or liver enzymes. These findings suggest a potential sex-specific effect of probiotic supplementation on antioxidant defense. However, results should be interpreted cautiously given the modest effect. Adequately powered clinical trials are warranted to confirm these findings.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.